Document is current
Any future updates will be listed below
-
Authors
Connor, Sydney
Zhang, Jiajia
Caushi, Justina
Zhang, Boyang
Zeng, Zhen
Sanber, Khaled
Pereira, Gavin
Anagnostou, Valsamo
Tam, Ada
Ionta, Nicholas
Housseau, Franck
Forde, Patrick
Ji, Hongkai
Pardoll, Andrew
Smith, Kellie
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02259621 at ClinicalTrials.govDocuments that mention this clinical trial
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.286
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2020-001282
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.327
293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.293
1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients
https://doi.org/10.1136/jitc-2023-sitc2023.1004
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0538
878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0878
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.665
57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0057
1255 Longitudinal assessment of the gut microbiome and its association with treatment response in patients with non-small cell lung cancer receiving neoadjuvant immunotherapy
https://doi.org/10.1136/jitc-2024-sitc2024.1255
